Navigating weight loss: The employer’s guide to a new comprehensive weight care agenda
Navigating Weight Loss:
The employer's guide to a new comprehensive weight care agenda
Sponsored by
The class of weight loss medication is seeing a spike in consumer popularity, driving employers to explore what the path to adoption looks like.
In EBN's first digital magazine of 2025, employers are ready to help employees stick to their resolutions around health and well-being.
On-site access to healthcare keeps workers and their families up to date on their health and ahead of major issues.
Data shows a noticeable decline in obesity among those taking medications such as Ozempic and Zepbound.
These efforts and expectations center around improving health outcomes while cutting costs.
Eli Lilly will begin offering vials of its best-selling weight-loss drug, Zepbound, through Ro's telehealth platform.
By focusing on behavioral changes around food, people are better able to lose weight and keep it off long-term.